Loading clinical trials...
Loading clinical trials...
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
Conditions
Interventions
RSV (GSK3389245A) lower dose formulation vaccine
RSV (GSK3389245A) higher dose formulation vaccine
+5 more
Locations
37
United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Nampa, Idaho, United States
GSK Investigational Site
Louisville, Kentucky, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil
GSK Investigational Site
Ribeirão Preto, São Paulo, Brazil
Start Date
April 8, 2019
Primary Completion Date
January 16, 2020
Completion Date
July 22, 2021
Last Updated
July 27, 2022
NCT07220109
NCT07092865
NCT07239583
NCT04732871
NCT06534892
NCT04919109
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions